ReNeuron Group appoints Iain Ross to its Board as Non-Executive Chairman

– UK, Bridgend –  ReNeuron Group plc (LON: RENE), a UK-based global leader in the development of cell-based therapeutics, today announced the appointment of Iain Ross to its Board as a Non-Executive Director and Chairman of the Board of Directors effective immediately, succeeding Dr. Tim Corn who is stepping down as Board Chairman, but will remain as a Non-Executive Director.

“We are delighted to welcome Iain to the ReNeuron team as Non-Executive Director and Chairman. Iain has considerable experience with commercially successful international lifescience businesses and we welcome his support as we enter into a period where we expect to reach important, data-driven value inflection points across our programmes over the next 12 months.” said CEO, Olav Hellebø.

About Iain Ross

Iain Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years. He held senior commercial roles at Sandoz, Fisons, and Hoffman La Roche before moving into the biotechnology sector where he has been Chairman, CEO, and Director of several international biotechnology companies including Celltech Group plc, Quadrant Healthcare plc, and Redx Pharma plc.

Currently, he is the Non-Executive Chairman at Silence Therapeutics PLC (LSE/NASDAQ) and Kazia Therapeutics Limited (ASX/NASDAQ). Mr. Ross is a qualified Chartered Director, Fellow of the Institute of Directors, and Honorary Fellow of Royal Holloway, London University.

Iain Ross commented: “I am delighted to be joining Reneuron at such a pivotal time and look forward to working with the Board & Management and to ensuring a significant uplift in shareholder value over the next few years.”

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop ‘off the shelf’ stem cell treatments for diseases with significant unmet needs. The Company’s lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalized induced pluripotent stem cell platform to make allogeneic tissue cells of choice; in-house programs are currently focused on treatments for blood cancers and diabetes.

For more information: http://www.reneuron.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.